Padagis Seeks To Challenge Hikma’s Kloxxado

Naloxone 8mg Nasal Spray Is Among Firm’s Latest First-To-File Targets

Padagis has filed an ANDA for a naloxone 8mg nasal spray

More from Legal & IP

More from Generics Bulletin